[Teicoplanin in otorhinolaryngology].
In this study the clinical microbiologic efficacy of a new antibiotic, Teicoplanin, has been reported. Teicoplanin was given to both male and female patients (200 or 400 mg/die doses) suffering from ORL infections. The microbial flora of the inflammatory focus was checked before and after antibiotic administration. Complete microbiologic eradication occurred in 13 cases of the 18 examined; in 3 cases was observed reinfection and in 2 cases the isolates were not sensitive to the antibiotic tested.
Cavallo
G P
GP
Clinica Otorinolaringoiatrica dell'Università di Torino.
Malcangi
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy / Q000382:microbiology; D017334:Teicoplanin
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin
La teicoplanina in otorinolaringoiatria.